vida: extract claims from 2026-04-29-9amhealth-waltz-novo-dte-glp1-access-2026

- Source: inbox/queue/2026-04-29-9amhealth-waltz-novo-dte-glp1-access-2026.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md

@@ -13,7 +13,7 @@ related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category
 supports: ["Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients"]
 reweave_edges: ["Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias|supports|2026-04-14", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients|supports|2026-04-14"]
 sourced_from: ["inbox/archive/health/2026-04-13-kff-glp1-access-inversion-by-state-income.md"]
-related: ["glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence"]
+related: ["glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access"]
 ---
 
 # GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs
@@ -39,3 +39,10 @@ The Medicare GLP-1 Bridge program demonstrates that access inversion operates at
 **Source:** KFF 2025 poll condition-specific usage
 
 Among patients with diagnosed conditions showing clear clinical benefit, uptake remains limited: 45% of diabetes patients and 29% of heart disease patients currently using GLP-1s. Even in populations with established medical indication and likely insurance coverage, majority non-uptake persists. The 56% affordability difficulty rate among current users demonstrates cost barriers operate even after initial access is achieved.
+
+
+## Extending Evidence
+
+**Source:** HR Brew December 2025, 9amHealth partnership announcements
+
+The utilization vs. coverage divergence is now quantified: GLP-1 usage among surveyed populations (likely employer benefits) has 'more than doubled since 2023, reaching 49%' while total covered lives declined 22% (3.6M → 2.8M). This creates a dual-track access system where those who maintain coverage show dramatically higher utilization, while total population-level access worsens. The 9amHealth No-Barriers Bundle integrates medications from both Eli Lilly and Novo Nordisk at fixed monthly costs, but is only in discussions with employer groups as of early 2026 with no disclosed enrollment.

domains/health/manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-28-glp1-managed-access-operating-systems-payer-infr
 scope: structural
 sourcer: on/healthcare.tech
 challenges: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
-related: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
+related: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression"]
 ---
 
 # Manufacturer direct-to-employer GLP-1 channels launched 2026 represent structural challenge to PBM intermediation by offering 55-60 percent price compression while bypassing traditional pharmacy benefit architecture
@@ -39,3 +39,10 @@ But the structural challenge is real: if manufacturers can profitably deliver GL
 **Source:** PHTI December 2025 employer report
 
 Eli Lilly Employer Connect launched March 5, 2026 at $449/dose with partnerships across 15+ program administrators (GoodRx, Teladoc, Calibrate, Form Health, Waltz). Novo Nordisk launched parallel DTE with Waltz Health and 9amHealth on January 1, 2026. Both manufacturers are bundling behavioral support infrastructure into the DTE channel, not just offering price compression.
+
+
+## Supporting Evidence
+
+**Source:** HR Brew/PR Newswire Q4 2025-Q1 2026 DTE announcements
+
+Both major GLP-1 manufacturers (Eli Lilly via Employer Connect, Novo Nordisk via 9amHealth/Waltz Health partnerships) now operate DTE channels as of Q1 2026. Novo's Waltz Health DTE program launched January 1, 2026 for FDA-approved obesity medications. 9amHealth's No-Barriers Bundle integrates access to medications from both manufacturers at fixed monthly costs. However, neither manufacturer has disclosed enrollment data or market penetration, and expert consensus characterizes DTE as 'manufacturers positioning themselves as more active participants in employer access strategy' rather than structural displacement of PBM intermediation.

entities/health/waltz-health.md

@@ -0,0 +1,26 @@
+# Waltz Health
+
+**Type:** Healthcare access platform  
+**Domain:** GLP-1 direct-to-employer distribution  
+**Status:** Active (as of 2026-01)
+
+## Overview
+
+Waltz Health operates a direct-to-employer (DTE) access program for FDA-approved obesity medications, partnering with Novo Nordisk to bypass traditional PBM intermediation.
+
+## Timeline
+
+- **2026-01-01** — Launched DTE access program for FDA-approved obesity medications in partnership with Novo Nordisk
+
+## Business Model
+
+DTE channel for GLP-1 access, competing with traditional PBM distribution. No enrollment data or market penetration disclosed as of Q1 2026.
+
+## Market Position
+
+Part of the emerging manufacturer-direct distribution strategy alongside Eli Lilly's Employer Connect and 9amHealth's No-Barriers Bundle. Expert consensus characterizes DTE as 'incremental governance shift, not structural PBM displacement.'
+
+## Sources
+
+- HR Brew, December 2025
+- PR Newswire, January 2026

inbox/archive/health/2026-04-29-9amhealth-waltz-novo-dte-glp1-access-2026.md

@@ -7,10 +7,13 @@ date: 2025-12-19
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-29
 priority: medium
 tags: [GLP-1, direct-to-employer, Novo-Nordisk, 9amHealth, Waltz-Health, access, DTE, employer-benefits]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content